Key Points
- CEO sold 10,282 shares: CareDx CEO John Walter Hanna, Jr. sold 10,282 shares on April 16 at an average price of $21.12 for about $217,156, executed under a pre‑arranged Rule 10b5‑1 plan and reducing his stake by 1.50% to 676,475 shares (≈$14.29M).
- Mixed financial picture: CareDx missed quarterly EPS expectations ($0.12 vs. $0.24) despite 25.2% YoY revenue growth to $108.39M and remains unprofitable (negative net margin and ROE); analysts hold a consensus "Hold" with a $27.60 target and expect -0.04 EPS for the fiscal year.
CareDx, Inc. (NASDAQ:CDNA - Get Free Report) CEO John Walter Hanna, Jr. sold 10,282 shares of the firm's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $21.12, for a total value of $217,155.84. Following the completion of the transaction, the chief executive officer directly owned 676,475 shares in the company, valued at $14,287,152. This trade represents a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CareDx Price Performance
Shares of NASDAQ CDNA opened at $21.29 on Tuesday. CareDx, Inc. has a 1-year low of $10.96 and a 1-year high of $23.24. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -53.23 and a beta of 2.54. The business has a 50-day moving average of $18.31 and a 200-day moving average of $17.96.
CareDx (NASDAQ:CDNA - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.12). The company had revenue of $108.39 million for the quarter, compared to analysts' expectations of $102.76 million. CareDx had a negative net margin of 5.65% and a negative return on equity of 6.50%. The business's quarterly revenue was up 25.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.18 earnings per share. Research analysts expect that CareDx, Inc. will post -0.04 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on CDNA shares. Wall Street Zen cut shares of CareDx from a "buy" rating to a "hold" rating in a research report on Saturday, February 7th. BTIG Research lifted their price target on shares of CareDx from $25.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Weiss Ratings lowered shares of CareDx from a "hold (c-)" rating to a "sell (d)" rating in a report on Friday, February 27th. Craig Hallum cut shares of CareDx from a "buy" rating to a "hold" rating and set a $26.00 price objective for the company. in a research report on Tuesday, January 6th. Finally, Wells Fargo & Company lifted their target price on CareDx from $18.00 to $21.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 25th. Two research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $27.60.
Read Our Latest Research Report on CDNA
Institutional Trading of CareDx
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Paragon Associates & Paragon Associates II Joint Venture increased its position in shares of CareDx by 93.7% in the 3rd quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 425,000 shares of the company's stock worth $6,180,000 after purchasing an additional 205,597 shares during the last quarter. First Eagle Investment Management LLC lifted its position in shares of CareDx by 25.4% during the third quarter. First Eagle Investment Management LLC now owns 475,146 shares of the company's stock worth $6,909,000 after purchasing an additional 96,123 shares during the last quarter. ARK Investment Management LLC lifted its position in shares of CareDx by 3.4% during the third quarter. ARK Investment Management LLC now owns 2,170,625 shares of the company's stock worth $31,561,000 after purchasing an additional 70,468 shares during the last quarter. Aberdeen Group plc acquired a new position in CareDx in the fourth quarter worth about $6,506,000. Finally, Zweig DiMenna Associates LLC increased its holdings in CareDx by 153.8% in the third quarter. Zweig DiMenna Associates LLC now owns 575,000 shares of the company's stock valued at $8,360,000 after buying an additional 348,400 shares during the last quarter.
About CareDx
(
Get Free Report)
CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.
The company's core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
